Chondrial Therapeutics
About:
Chondrial Therapeutics is clinical-stage biotechnology that focuses on developing orphan drugs for mitochondrial diseases.
Top Investors: Deerfield, Deerfield Capital Management
Description:
Chondrial Therapeutics s a clinical-stage biotechnology company focused on the treatment of rare diseases. It is dedicated to the pursuit of scientific research leading to the treatment for Friedreich’s Ataxia and other mitochondrial diseases.
Total Funding Amount:
$49.4M
Estimated Revenue Range:
Less than $1M
Headquarters Location:
Bala Cynwyd, Pennsylvania, United States
Founded Date:
2013-01-01
Contact Email:
info(AT)chondrialtherapeutics.com
Founders:
R. Mark Payne
Number of Employees:
1-10
Last Funding Date:
2019-05-26
IPO Status:
Private
Industries:
© 2025 bioDAO.ai